McKesson Corp. reported fiscal first-quarter revenue of $97.8 billion, topping analysts’ average projection of $96.28 billion, and delivered adjusted earnings of $8.26 a share versus the expected $8.19. The Texas-based drug distributor raised its full-year fiscal 2026 profit forecast to $37.10–$37.90 a share from $36.90–$37.70, bracketing the current LSEG IBES consensus of $37.41. The company said the revised outlook reflects stronger first-quarter performance and continued demand for its pharmaceutical distribution and healthcare services.
CRH Plc. beats by $0.02, reports revs in-line; guides FY25 EPS in-line $crh
$MCK | McKesson Q1 26 Earnings: • Revenue: $97.8B (est. $96.28B) • Adjusted EPS: $8.26 (est. $8.19) • Sees FY Adj. EPS: $37.10 to $37.90 (prior $36.90 to $37.70)
McKesson beats by $0.12, beats on revs; guides FY26 EPS in-line $MCK